This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE state (1):

Inclisiran is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if:

  • there is a history of any of the following cardiovascular events:
    • acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
    • coronary or other arterial revascularisation procedures
    • coronary heart disease
    • schaemic stroke or
    • peripheral arterial disease, and
  • low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is
    • maximum tolerated statins with or without other lipid-lowering therapies or,
    • other lipid-lowering therapies when statins are not tolerated or are contraindicated, and
  • the company provides inclisiran according to the commercial arrangement

Note that there have been concerns raised concerning the NICE technology appraisal for inclisiran (2):

  • the Orion-9, Orion-10 and Orion-11 trials that the appraisal was based on had primary outcomes based on the change from baseline in participants' serum concentrations of LDL cholesterol - however LDL cholesterol is a surrogate outcome for cardiovascular disease, and doubts remain over whether improvements in surrogate endpoints are an accurate reflection of patient benefit
    • secondary outcomes included an exploratory cardiovascular endpoint -a composite of death, cardiac arrest, non-fatal myocardial infarction, and stroke - however the overall number of events was too low to draw conclusions
  • the study authors concluded that "NICE should reconsider its decision until patient relevant outcomes are available, and these, and all cost data, should be released for independent analysis"

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.